A Randomized, Phase I Study of DNA Vaccine OC-007 as a Booster Dose of COVID-19 Vaccine

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 8, 2023

Primary Completion Date

March 13, 2024

Study Completion Date

March 13, 2024

Conditions

COVID-19 Respiratory InfectionCOVID-19 Vaccine Adverse Reaction

Interventions

BIOLOGICAL

DNA vaccine OC-007

Plasmid DNA vaccine

OTHER

Placebo

0.9% NaCl solution

Trial Locations (1)

Phase I Study Unit, Karolinska University Hospital, Stockholm

All Listed Sponsors

lead

Matti Sällberg

OTHER